Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.67 |
| ▸ | MTOR | P42345 | 9/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.49 |
| ▸ | ATR | Q13535 | 3/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.49 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055635 | 0.91 | PIK3CA (0.73) | PIK3CAPIK3CDMTORCHEK1ATR | |
| SCHEMBL3054612 | 0.88 | PIK3CA (0.75) | PIK3CAPIK3CDMTORCHEK1ATR | |
| SCHEMBL3604970 | 0.86 | PIK3CA (0.72) | PIK3CAPIK3CDMTORCHEK1ATR | |
| SCHEMBL3599383 | 0.85 | PIK3CA (0.83) | PIK3CAPIK3CDMTORCHEK1ATR | |
| SCHEMBL3601697 | 0.84 | PIK3CA (0.69) | PIK3CAPIK3CDMTORCHEK1ATR | |
| SCHEMBL3604184 | 0.83 | PIK3CA (0.67) | PIK3CAPIK3CDMTORCHEK1ATR | |
| SCHEMBL8096450 | 0.81 | KMT2A (0.53) | PIK3CAPIK3CDMTORATR | |
| SCHEMBL3066995 | 0.81 | PIK3CA (0.60) | PIK3CAPIK3CDMTORCHEK1ATR | |
| SCHEMBL3061831 | 0.80 | PIK3CA (0.81) | PIK3CAPIK3CDMTORCHEK1ATR | |
| SCHEMBL3065746 | 0.80 | MTOR (0.75) | PIK3CAPIK3CDMTORATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261723-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261723-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261723-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261723-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MTOR, PIK3CA, TYMP | PIK3CA 2/4885PIK3CD 4/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.